Targeting non-coding RNA for the therapy of renal disease

Research output: Contribution to journalReview articlepeer-review

Abstract / Description of output

MicroRNAs (miRNA) are small non-coding RNA molecules representing a novel class of endogenous negative regulators of gene expression. MiRNA have the ability to bind to specific regions in the 3'UTR of mRNA and repress gene expression through interaction with the RNA induced silencing complex (RISC). They have now been implicated in the pathophysiology of many kidney diseases, including the onset and progression of tubulointerstitial and glomerulosclerosis and have potential as biomarkers and as novel targets for treatment. The unique feature of miRNAs to target multiple mRNAs defines that targeting a particular miRNA for therapy could have a dramatic effect on the disease process. This review will focus on our current understanding of the role of miRNA in renal diseases, including diabetes, renal fibrosis, IgA nephropathy and explore the miRNA targets which represent the most promising in terms of clinical translation.

Original languageEnglish
Pages (from-to)70-7
Number of pages8
JournalCurrent Opinion in Pharmacology
Early online date26 Feb 2016
Publication statusPublished - Apr 2016


Dive into the research topics of 'Targeting non-coding RNA for the therapy of renal disease'. Together they form a unique fingerprint.

Cite this